Study Phases

 

Phase 0B

Viro-Gen has commissioned a research laboratory with extensive Genomic Research capabilities. Here, Viro-Gen will finalise an important aspect of IP development before taking the company public.

The Phase 0B research will therefore:

Establish the signalling pathways between Protein “X” and the viral infectivity protein of HIV

Confirm the binding capabilities of Protein “X” to the viral infectivity proteins of Hepatitis and SARS viruses

Establish the signalling pathways between Protein “X” and the viral infectivity proteins of Hepatitis and SARS viruses

The study is expected to take three months to complete.

Phase 0C

Viro-Gen will then carry out a short study relating to how Protein “X” levels can be increased in a human host to the desired quantity.

This work will be aided by the ready availability on the market of a Protein “X”-encoded viral vector which vector may be used to instruct the body to produce specific amounts of Protein “X” in the bloodstream. There being no need to develop a Protein “X”-encoded vector from scratch, Phase 0C will:

Use an existing viral vector that Viro-Gen has found on the market;

Confirm the quantity of that vector that produces the desired quantity of Protein “X”

Phase 0B and 0C will be completed in 2022 at which point Viro-Gen will consider whether to exit from the technology or to take the company public in order to carry out clinical trials on animal and human subjects.

Phase 0B and 0C will be completed in 2022 at which point Viro-Gen will consider whether to exit from the technology or to take the company public in order to carry out clinical trials on animal and human subjects.

Our Address

PMA House, Block B, Ground Floor,
Tijger Vallei Office Park, Silver Lakes Road,
Silver Lakes, Pretoria, 0081

    Contact Us

Tel No: +27 (0)87 092 5148
Email:  info@viro-gen.com